Table 2.
Antifungal susceptibility of Candida isolates from patients with COVID-19-associated candidasis36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53??
| Candida species | FLU | VOR | ITR | POS | MIC | CAS | ANI | AmB | 5-FU |
|---|---|---|---|---|---|---|---|---|---|
| C. auris | 8/75 (10.7) | 32/45 (71.1) | 54/55 (98.2) | 54/60 (90.0) | 70/72 (97.2) | 28/65 (43.1) | 36/36 (100) | ||
| C. albicans | 30/32 (93.8) | 24/25 (96.0) | 17/20 (85.0) | 9/12 (75.0) | 26/26 (100) | 10/12 (83.3) | 17/19 (89.5) | 23/23 (100) | 15/17 (88.2) |
| C. glabrata | 0/11 (0) | 10/10 (100) | 10/10 (100) | 7/7 (100) | 6/7 (85.7) | 2/5 (40) | 7/10 (70.0) | 10/10 (100) | 5/5 (100) |
| C. tropicalis | 5/5 (100) | 5/5 (100) | 4/4 (100) | 1/1 (100) | 5/5 (100) | 0/1 (0) | 19/19 (100) | 19/19 (100) | 19/19 (100) |
| C. krusei | 2/2 (100) | 1/1 (100) | 2/2 (100) | 2/2 (100) | 0/1 (0) | 2/2 (100) | 2/2 (100) | 2/2 (100) | |
| C. parapsilosis | 2/3 (66.7) | 3/3 (100) | 3/3 (100) | 3/3 (100) | 3/3 (100) | 1/1 (100) | 1/1 (100) | 1/1 (100) |
Data are expressed as the numbers of susceptible isolates/total tested isolates (%).
Note: FLU, fluconazole; VOR, voriconazole; ITR, itraconazole; POS, posaconazole; MIC, micafungin; CAS, caspofungin; ANI, anidulafungin; AmB, amphotericin B; 5-FU, flucytosine.